Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients

Mike Wenzel MD, BSc1,2 | Claudia Collà Ruvolo MD2,3 | Christoph Würnschimmel MD2,4 | Luigi Nocera MD2,5 | Zhe Tian MSc2 | Fred Saad MD PhD2 | Alberto Briganti MD PhD3 | Derya Tilki MD, PhD4,6 | Markus Graefen MD, PhD4 | Andreas Becker MD, PhD1 | Frederik Roos MD, PhD1 | Philipp Mandel MD, PhD1 | Felix K. H. Chun MD, PhD1 | Pierre I. Karakiewicz MD, PhD2

1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany
2Division of Urology, Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada
3Department of Neurosciences, Reproductive Sciences, and Odontostomatology, University of Naples Federico II, Naples, Italy
4Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
5Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy
6Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Correspondence
Mike Wenzel, MD, Department of Urology, University Hospital Frankfurt, Theodor-Stern Kai 7, 60590 Frankfurt, Germany. Email: Mike.Wenzel@kgu.de

Abstract

Background: The survival benefit of primary external beam radiation therapy (EBRT) has never been formally tested in elderly men who were newly diagnosed with metastatic prostate cancer (mPCa). We hypothesized that elderly patients may not benefit of EBRT to the extent as younger newly diagnosed mPCa patients, due to shorter life expectancy.

Methods: We relied on Surveillance, Epidemiology and End Results (2004–2016) to identify elderly newly diagnosed mPCa patients, aged >75 years. Kaplan–Meier, univariable and multivariable Cox regression models, as well as Competing Risks Regression models tested the effect of EBRT versus no EBRT on overall mortality (OM) and cancer-specific mortality (CSM).

Results: Of 6556 patients, 1105 received EBRT (16.9%). M1b stage was predominant in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). Median overall survival (OS) was 23 months for EBRT and 23 months for no EBRT (hazard ratio [HR]: 0.97, p = 0.6). Similarly, median cancer-specific survival (CSS) was 29 months for EBRT versus 30 months for no EBRT (HR: 1.04, p = 0.4). After additional multivariable adjustment, EBRT was not associated with lower OM or lower CSM in the entire cohort, as well as after stratification for M1b and M1c substages.

Conclusions: In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.

KEYWORDS
cancer-specific survival, EBRT, elderly, local treatment, overall survival

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. The Prostate published by Wiley Periodicals LLC.
INTRODUCTION

The current National Comprehensive Cancer Network (NCCN) and European Association of Urology (EAU) guidelines recommend local treatment including external beam radiation therapy (EBRT) in primary newly diagnosed, low volume metastatic prostate cancer (mPCA) patients, regardless of patient age. These recommendations are predominately based on the STAMPEDE trial that enrolled 2061 patients. Of those, only 12.5% were aged 73 years or older. In consequence, data supporting the use of EBRT in elderly (75 years and older) are not excessively robust. The uncertainty about EBRT benefits in elderly patients is further compounded by the HORRAD trial that failed to confirm the survival benefit of EBRT, not only in elderly but in all newly diagnosed mPCA patients. Five recent retrospective large-scale or institutional studies also addressed EBRT in newly diagnosed mPCA patients. However, stratification between elderly versus others was not made. In consequence, there is uncertainty about the added benefit of EBRT to systematic therapy in elderly men who were newly diagnosed with mPCA.

To address this uncertainty, we tested whether EBRT is associated with lower overall survival (OS) and/or lowers cancer-specific mortality (CSM) in elderly men (>75 years) who were newly diagnosed with mPCA. The rationale for using the >75 years of age cut-off was based on the United States Social Security Life Tables that indicate less than 10-year life expectancy in those individuals, even when mPCA does not represent a competing cause of mortality. We tested our hypothesis within the Surveillance, Epidemiology and End Results (SEER) database 2004–2016.

MATERIALS AND METHODS

Study population

The current SEER database samples approximately 35% of the United States population and approximates it in demographic composition and cancer incidence. Within SEER database (2004–2016), we identified patients >75 years old with newly diagnosed metastatic, histologically confirmed adenocarcinoma of the prostate (International Classification of Disease for Oncology [ICD-O-3] code 8140 site code C61.9). Autopsy cases or cases based on death certificates and non-primary prostate cancers were excluded. Elderly patients were defined as those aged >75 years. The predictor of interest consisted of EBRT versus no EBRT. Stratification of overall mortality (OM) and CSM was performed according to M1 substages, in accordance with TNM classification: M1a versus M1b versus M1c versus M1x. These selection criteria resulted in a cohort of 6,556 elderly men who were newly diagnosed with mPCA patients.

Statistical analyses

Descriptive statistics included frequencies and proportions for categorical variables. Means, medians, and interquartile ranges (IQR) were reported for continuously coded variables. The χ² tested the statistical significance in proportions’ differences. The t test and Kruskal–Wallis test examined the statistical significance of means’ and distributions’ differences.

Kaplan–Meier and univariable, as well as multivariable Cox regression models after adjustment for covariates (PSA [prostate-specific antigen], age, Grade Group at biopsy, cT-stage, cN-stage, and race/ethnicity) tested the effect of EBRT in elderly men who were newly diagnosed with mPCA patients on OM and CSM.

Finally, to adjust for the potential confounding effect of other cause mortality (OCM) we also relied on competing risks regression (CRR). Here, the endpoint of interest consisted of CSM after adjustment for OCM. Additionally, propensity score matching was performed for comparisons between EBRT versus no EBRT. 1:4 matching relied on exact matching for age at diagnosis, PSA, M-stage (M1a vs. M1b vs. M1c vs. M1x) T-stage (T1-2 vs. T3-4), cN-stage (cN0 vs. cN1 vs. cNx), and Grade Groups (I vs. II vs. III, IV vs. V vs. unknown). Additional multivariable adjustment was performed for administration of chemotherapy and race/ethnicity. All tests were two-sided with a level of significance set at p < 0.05 and R software environment for statistical computing and graphics (version 3.4.3) was used for all analyses.

RESULTS

Descriptive characteristics of the study population

Of 6556 elderly men who were newly diagnosed with mPCA (Tables 1), 1105 received EBRT (16.9%) versus 5451 no EBRT (83.1%). Median age at diagnosis was 81 years (IQR: 78–84) for EBRT versus 82 years (IQR: 78–85) for no EBRT (p < 0.01). Moreover, median PSA was 81.5 ng/ml (IQR: 22.6–98.0) in the EBRT versus 98 ng/ml (IQR: 29.5–98.0) in the no EBRT group (p < 0.01). M1b stage predominated in both EBRT (n = 823; 74.5%) and no EBRT (n = 3908; 71.7%, p = 0.06) groups, followed by M1c (n = 211; 19.1% vs. n = 1042; 19.1%, p = 1) and M1a (n = 29; 2.6% vs. n = 268; 4.9%, p < 0.01). No clinically meaningful or significant differences were recorded for cT-stage, cN-stage, Grade Group at biopsy or chemotherapy administration or regional differences. Median follow up was 15 months in EBRT versus 18 months in the no EBRT group (p < 0.01).

OM and cancer-specific mortality in the overall cohort

In the overall cohort, Kaplan–Meier analyses revealed no clinically meaningful or statistically significant differences in OS or CSS values between EBRT versus no EBRT in elderly men who were newly diagnosed with mPCA. Median OS (Figure 1A) was 23 months for EBRT and 23 months for no EBRT patients (hazard ratio [HR]: 0.97,
3.3 | OM and cancer-specific mortality according to M1b and M1c substages

Kaplan–Meier plots demonstrated that in subgroup analyses according to M1 substages (M1b and M1c), EBRT was also unrelated to OS or CSS (Figures 2–3). In M1b patients regarding OS, median OS was 24 months after EBRT and 24 months after no EBRT (HR: 0.98, CI: 0.90–1.08, p = 0.7) in Kaplan–Meier plots. In M1b patients...
**FIGURE 1** Kaplan–Meier plot illustrating (A) overall mortality (OM) and (B) cancer-specific mortality (CSM) in the overall cohort of elderly men who were newly diagnosed with metastatic prostate cancer, comparing external beam radiation therapy (EBRT) versus no EBRT. CI, confidence interval; HR, hazard ratio; mPCa, metastatic prostate cancer. [Color figure can be viewed at wileyonlinelibrary.com]

**TABLE 2** Univariable and multivariable Cox regression models in elderly men who were newly diagnosed with metastatic prostate cancer predicting overall mortality (OM) and cancer-specific mortality (CSM)

|                | OM Univariable | OM Multivariable | CSM Univariable | CSM Multivariable |
|----------------|---------------|------------------|-----------------|-------------------|
|                | HR (95% CI)   | p value          | HR (95% CI)     | p value           |
| No EBRT        | Ref           | -                | Ref             | -                 |
| EBRt           | 0.97 (0.90–1.06) | 0.6              | 1.04 (0.96–1.13) | 0.3              |
| Age            | 1.06 (1.05–1.06) | <0.001          | 1.05 (1.04–1.06) | <0.001           |
| PSA            | 1.00 (1.00–1.01) | <0.001          | 1.00 (1.00–1.00) | <0.001           |
| Grade Group I  | Ref           | -                | Ref             | -                 |
| Grade Group II-III | 1.18 (0.85–1.65) | 0.3             | 0.97 (0.69–1.36) | 0.9              |
| Grade Group IV-V | 1.43 (1.05–1.95) | 0.02          | 1.11 (0.82–1.52) | 0.5              |
| Grade Group unknown | 1.74 (1.29–2.36) | <0.01        | 1.28 (0.94–1.74) | 0.1              |
| cT1 stage      | Ref           | -                | Ref             | -                 |
| cT2            | 1.02 (0.94–1.10) | 0.6              | 0.95 (0.88–1.03) | 0.3              |
| cT3            | 1.08 (0.96–1.21) | 0.2              | 1.03 (0.92–1.16) | 0.6              |
| cT4            | 1.52 (1.38–1.68) | <0.001          | 1.35 (1.22–1.49) | <0.001           |
| cTx            | 1.40 (1.28–1.53) | <0.001          | 1.19 (1.09–1.31) | <0.001           |
| cN0 stage      | Ref           | -                | Ref             | -                 |
| cN1            | 1.09 (1.01–1.18) | 0.035          | 1.03 (0.95–1.11) | 0.5              |
| cNx            | 1.19 (1.11–1.27) | <0.001          | 1.03 (0.96–1.11) | 0.4              |
| Caucasian      | Ref           | -                | Ref             | -                 |
| African American | 1.05 (0.96–1.15) | 0.3          | 1.06 (0.97–1.16) | 0.2              |
| Hispanic       | 0.86 (0.77–0.95) | <0.01       | 0.86 (0.78–0.96) | <0.01            |
| Asian          | 0.68 (0.60–0.78) | <0.001       | 0.68 (0.59–0.77) | <0.001           |

**Abbreviations:** CI, confidence interval; EBRt, external beam radiation therapy; HR, hazard ratio; PSA, prostate-specific antigen.
regarding CSS, median CSS was 30 months after EBRT versus 32 months after no EBRT (HR: 1.05, CI: 0.95–1.17, p = 0.4) in Kaplan–Meier plots.

After multivariable Cox regression addressing OM in M1b substage, EBRT failed to demonstrate statistical significance (HR: 1.04, p = 0.4). In multivariable Cox regression models addressing CSM in M1b substage, EBRT was associated with higher CSM (HR: 1.12, CI: 1.00–1.24, p = 0.04).

In M1c patients regarding OS, median OS was 16 months after EBRT versus 17 months after no EBRT (HR: 0.92, CI: 0.77–1.09, p = 0.3). In M1c patients regarding CSS, median CSS was 20 months after EBRT versus 22 months after no EBRT (HR: 0.96, CI: 0.79–1.16, p = 0.7).

In multivariable Cox regression models addressing OM in M1c substage, EBRT was also unrelated to OM (HR: 1.03, p = 0.7).

In multivariable Cox regression models addressing CSM in M1c substage, EBRT associated with higher CSM (HR: 1.09, p = 0.4). Due to insufficient number of observations, stratified analyses within the M1a substages could not be completed.

### 3.4 CRR analyses with propensity score matching

In the final part of the study, we relied on CRR to adjust for the potentially confounding effect of OCM on CSM. Additionally, we also relied on 1:4 propensity score matching to adjust for residual patient and tumor characteristics that may remain even after multivariable adjustment. Before matching, 680 EBRT and 3646 no EBRT patients were available. After 4:1 propensity score matching for age, PSA, M-stage, stage, and Grade Group, 674 EBRT and 2696 no EBRT
patients remained and were included in further analyses. After matching, no residual differences for matched variables remained.

After propensity score matching (Figure 4), in cumulative incidence plots that adjusted for OCM, 5-year CSM was 63.9% after EBRT versus 61.5% after no EBRT patients (p = 0.1). After OCM and additional multivariable adjustment (Table 3), EBRT was unrelated to CSM (HR: 1.07, p = 0.1).

## 4 | DISCUSSION

We postulated that the added benefit of EBRT in elderly men who were newly diagnosed with mPCa cannot be claimed without a significant amount of uncertainty. The latter originates from a small proportion of elderly patients that were enrolled in the STAMPEDE trial (12.5% > 73 years aged), where added benefit of EBRT was显著地 associated with a survival advantage in elderly North American men who were newly diagnosed with mPCa. This observation partially validates the comparability of patient tumor burdens within the current study, relative to that of the STAMPEDE trial. This observation is particularly important since the strict definition of low volume mPCa used in the STAMPEDE trial could not be directly applied to the SEER database. Additionally, our cohort consisted of 6556 elderly men (>75 years) who were newly diagnosed with mPCa. Conversely, only 12.5% of the STAMPEDE trial patients were aged 75 years or higher (n = 258). Therefore, the current study represents a substantially more robust source of data for elderly men who were newly diagnosed with mPCa. Moreover, our study focused on North American elderly men who were newly diagnosed with mPCa. Such individuals were not included in the STAMPEDE trial. In consequence, our study provides robust cohort of elderly men who were newly diagnosed with mPCa. In addition, it also provides a robust sample of North American elderly men who were newly diagnosed with mPCa. All of the above points validate the importance of our contribution to the knowledge of EBRT in the context of newly diagnosed mPCa patients.

Third, we recorded no decrease in OM or CSM in EBRT exposed patients, relative to their EBRT unexposed counterparts in elderly men who were newly diagnosed with mPCa. Regardless of analysis type (Kaplan–Meier, Cox regression models, Cumulative Incidence, CRR), EBRT patients did not exhibit more favorable survival outcomes (OM and CSM) than their no EBRT counterparts. Finally, lack of mPCa survival outcomes after EBRT was equally recorded in Cox regression models and in CRR models that accounted for potential bias related to OCM. Taken together, these observations indicate that EBRT neither clearly nor convincingly associated with a survival advantage in elderly North American men who were newly diagnosed with mPCa. These finding are in contrast to studies focusing on elderly patients with localized prostate cancer, who exhibited a survival benefit with EBRT, relative to their counterparts in whom EBRT was not delivered. It is also of note that EBRT-related side effects may be especially important to consider in elderly men who were newly diagnosed with mPCa due to higher toxicity rates that have been well documented in elderly prostate cancer patients, relative to their younger counterparts.

Our work has limitations and should be interpreted in the context of its retrospective and population-based design. First, the variables that we relied on in our analyses do not approximate the detail...
TABLE 3 Univariable and multivariable competing-risks regression models for elderly men who were diagnosed with metastatic prostate cancer after 1:4 matching for age at diagnosis, PSA, M-stage (M1a vs. M1b vs. M1c vs. M1x) T-stage (T1-2 vs. T3-4), cN-stage (cN0 vs. cN1 vs. cNx) and Grade Group (I vs. II vs. III, IV vs. V vs. unknown) predicting cancer-specific mortality (CSM) and other cause mortality (OCM)

| Treatment          | CSM Univariable | CSM Multivariable | OCM Univariable | OCM Multivariable |
|--------------------|-----------------|-------------------|-----------------|-------------------|
|                   | HR (95% CI) p    |                   | HR (95% CI) p   |                   |
| Treatment          |                 |                   |                 |                   |
| No EBRT            | 1.00 (Ref.) p    | 1.00 (Ref.)       | 1.00 (Ref.)     | 1.00 (Ref.)       |
| EBRT               | 1.08 (0.98–1.18) | 0.11              | 1.07 (0.98–1.18)| 0.1               |
| Chemotherapy       |                 |                   |                 |                   |
| No/Unknown         | 1.00 (Ref.) p    | 1.00 (Ref.)       | 1.00 (Ref.)     | 1.00 (Ref.)       |
| Yes                | 1.15 (0.97–1.37) | 0.1               | 1.14 (0.96–1.36)| 0.1               |
| Race/ethnicity     |                 |                   |                 |                   |
| Caucasian          | 1.00 (Ref.) p    | 1.00 (Ref.)       | 1.00 (Ref.)     | 1.00 (Ref.)       |
| African-American   | 0.99 (0.89–1.11) | 0.9               | 1.00 (0.89–1.11)| 0.9               |
| Hispanic           | 0.96 (0.84–1.08) | 0.45              | 0.96 (0.85–1.09)| 0.5               |
| Asian              | 0.74 (0.64–0.86) | <0.001            | 0.74 (0.64–0.87)| <0.001            |

Abbreviations: CI, confidence interval; EBRT, external beam radiation therapy; HR, hazard ratio.

of recorded variables in prospective randomized studies. In consequence, the amount of detail that could be used for adjustment of potentially confounding variables is not comparable to prospective studies or high-quality, albeit smaller scale, institutional datasets. Second, no information regarding comorbidities is available in the SEER-database. We compensated for this limitation by relying on CRR models that adjust for OCM. Here, we adjusted for the most important comorbidities that may resulted in OCM. Additionally, none of potentially important other cancer-control outcomes, such as biochemical recurrence, progression-free survival or metastatic progression were available. We could not adjust for type or length of androgen deprivation therapy (ADT). However, it can be assumed that almost all newly diagnosed mPCa patients received ADT to reduce the risk of CSM. Moreover, we could not account for selection biases related to primary treatment assignment (EBRT vs. no EBRT). Finally, no meaningful analyses could be conducted for M1a substage due to sample size limitations.

5 | CONCLUSION

In elderly men who were newly diagnosed with mPCa, EBRT does not affect OS or CSS. In consequence, our findings question the added value of local EBRT in elderly newly diagnosed mPCa patients.

ACKNOWLEDGMENT

The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

DATA AVAILABILITY STATEMENT

All data generated for this analysis were from the SEER 18 database. The code for the analyses will be made available after request.

ORCID

Mike Wenzel http://orcid.org/0000-0002-4338-0889
Christoph Wünschimmel http://orcid.org/0000-0001-7891-4791
Luigi Nocera http://orcid.org/0000-0003-3554-8139
Derya Tilki http://orcid.org/0000-0001-7033-1380

REFERENCES

1. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020.
2. Mottet N, van den Bergh R, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Eur Urol. 2020;79:243-262.
3. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353-2366.
4. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410-418.
5. Knipper S, Beyer B, Mandel P, et al. Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with
6. Pompe RS, Tilki D, Preisser F, et al. Survival benefit of local versus no local treatment for metastatic prostate cancer: Impact of baseline PSA and metastatic substages. Prostate. 2018;78(10):753-757.

7. Stolzenbach LF, Deuker M, Collà Ruvolo C, et al. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer Prostata Dis. 2020;24:253-260.

8. Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835-2842.

9. Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77(6):559-572.

10. Leyh Bannurah S-R, Gazdovich S, Budäus L, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72(1):118-124.

11. Wenzel M, Würnschimmel C, Nocera L, et al. Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. Eur Urol Focus. 2021;52405-4569(21):00109-7. doi:10.1016/j.euf.2021.04.003

12. Brierley JD, Gospodorowicz MK, Wittekind C. The TNM Classification of Malignant Tumours. Wiley Blackwell; 2017.

13. Würnschimmel C, Wenzel M, Collà Ruvolo C, et al. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities [published online ahead of print May 12, 2021]. World J Urol. doi:10.1007/s00345-021-03720-7

14. Würnschimmel C, Wenzel M, Collà Ruvolo C, et al. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. Int J Urol. 2021;28(8):862-869. doi:10.1111/iju.14595

15. Dell’oglio P, Boehm K, Trudeau V, et al. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2016;96(5):1037-1045.

16. Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol. 2011;59(1):88-95.

17. Knipper S, Dzyuba-Negrean C, Palumbo C, et al. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. Int Urol Nephrol. 2020;52(1):59-66.

18. Wilson JM, Dearnaley DP, Syndikus I, et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. Int J Radiat Oncol Biol Phys. 2018;100(5):1179-1189.

19. Löser A, Beyer B, Carl CO, et al. Toxicity and risk factors after combined high-dose-rate brachytherapy and external beam radiation therapy in men ≥75 years with localized prostate cancer. Strahlenther Onkol. 2019;195(5):374-382.

20. Wenzel M, Würnschimmel C, Chierigo F, et al. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. Prostate. 2021;81(11):728-735. doi:10.1002/pros.24169

21. Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal trends in costs of palliative radiation for metastatic prostate cancer. J Palliat Med. 2015;18(11):933-939.

22. Dell’oglio P, Bandini M, Leyh-Bannurah S-R, et al. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urol Oncol. 2018;36(5):239.e9-239.e15.

23. Tay KJ, Moul JW, Armstrong AJ. Management of prostate cancer in the elderly. Clin Geriatr Med. 2016;32(1):113-132.

How to cite this article: Wenzel M, Collà Ruvolo C, Würnschimmel C, et al. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. The Prostate. 2022;82:78-85. https://doi.org/10.1002/pros.24249